<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01846988</url>
  </required_header>
  <id_info>
    <org_study_id>CIN001APAP</org_study_id>
    <nct_id>NCT01846988</nct_id>
  </id_info>
  <brief_title>Comparing Auto-adjustable Positive Airway Pressure to Continuous Positive Airway Pressure in Children With Sleep Apnea</brief_title>
  <official_title>Efficacy of Auto-adjustable Positive Airway Pressure (APAP) in Pediatric Patients With Obstructive Sleep Apnea (OSA).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if auto-adjustable positive airway&#xD;
      pressure (APAP) is an effective way to treat obstructive sleep apnea (OSA) in children. APAP&#xD;
      is a device similar to continuous positive airway pressure (CPAP) that delivers pressure to&#xD;
      the upper airway (nose and throat) to keep the airway from collapsing while during sleep. The&#xD;
      difference is that APAP adjusts the pressure throughout the night with changes in resistance&#xD;
      during breathing, and CPAP gives the same amount of pressure the whole time it is worn. APAP&#xD;
      is currently widely used to treat adults with OSA, however, this device has not yet been&#xD;
      extensively studied in children.&#xD;
&#xD;
      There are two parts to this research study. Subjects will begin using APAP at the time of&#xD;
      enrollment for 4 to 8 weeks. The investigators will compare the pressure measured by the APAP&#xD;
      device over the 4-8 weeks with the pressure determined by a CPAP titration study. The&#xD;
      titration study is a second overnight sleep study that is routinely ordered when a child with&#xD;
      sleep apnea starts treatment with CPAP. It tells the doctor what CPAP setting should be used.&#xD;
&#xD;
      In the second part of this study The investigators will compare the effects of APAP with CPAP&#xD;
      to see what is reported as more comfortable and is used during more hours of sleep. This part&#xD;
      of the study will last about 8 weeks and each subject will use both CPAP and APAP for 4 weeks&#xD;
      each.&#xD;
&#xD;
      Currently when someone is diagnosed with OSA there is a delay in starting treatment with CPAP&#xD;
      until the results of the titration study are available. In this research, patients could be&#xD;
      allowed to immediately start treatment with APAP. If APAP is found to be as safe and&#xD;
      effective as regular CPAP, treatment with APAP could be used as an alternative to CPAP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a small clinical trial to test the feasibility of using APAP in children with sleep&#xD;
      apnea.&#xD;
&#xD;
      Continuous positive airway pressure (CPAP) is commonly used to treat OSA by delivering a&#xD;
      predetermined amount of positive pressure to the patient's upper airway in order to reduce&#xD;
      the collapsibility of airway structures during sleep. The commonly accepted method for&#xD;
      determining the appropriate pressure setting for children with OSA is through an in-hospital&#xD;
      overnight CPAP titration study. Another commonly used treatment modality in adults with OSA&#xD;
      is auto-adjustable positive airway pressure (APAP), in which airway patency is maintained by&#xD;
      adjusting pressure delivery through the night depending on the needs of the patient as&#xD;
      determined by the device. Benefits of APAP compared with CPAP include the ability to initiate&#xD;
      therapy without an inpatient CPAP titration study, resulting in more prompt establishment of&#xD;
      treatment and cost-savings. Patient adherence may also be significantly improved as the&#xD;
      pressure delivered is appropriate for sleep stage and patient position, resulting in greater&#xD;
      patient comfort. Utility and efficacy of APAP compared to CPAP have never been evaluated in&#xD;
      the pediatric population.&#xD;
&#xD;
      The aim of this study is to establish APAP as an effective means of assessing CPAP pressure&#xD;
      for OSA in children, and to determine if APAP therapy confers better treatment adherence and&#xD;
      quality of life compared to traditional CPAP. The investigators hypothesize that APAP can&#xD;
      effectively approximate the pressure determined by CPAP titration study, that APAP is&#xD;
      superior to fixed CPAP in terms of treatment success, and that adherence to therapy will be&#xD;
      improved with APAP compared to CPAP.&#xD;
&#xD;
      Forty patients aged 5-20 years will be enrolled in the study. These subjects will be&#xD;
      recruited from the pediatric pulmonary or pediatric sleep clinic at Cincinnati Children's&#xD;
      Hospital. Patients who are suspected of having OSA will be referred in the usual manner to&#xD;
      the sleep center for diagnostic sleep study (PSG). Following the establishment of OSA&#xD;
      diagnosis and subsequent enrollment in the study, the subject will begin therapy with APAP&#xD;
      which will continue for 4 to 8 weeks. In that period of time the clinically ordered&#xD;
      in-hospital CPAP titration study will be completed. The subject will then be randomized to&#xD;
      either traditional fixed pressure CPAP at the pressure determined by in-hospital titration or&#xD;
      APAP. The subject will receive 4 weeks of treatment in the randomized group (CPAP or APAP)&#xD;
      then crossover to 4 weeks in the alternate group (CPAP or APAP). Both patient and researcher&#xD;
      will be blinded to the randomization of pressure modality. The total study period will range&#xD;
      from 12-16 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference Between Optimal Pressure (cm H2O) Derived From APAP run-in Period Versus Result of CPAP Titration Study</measure>
    <time_frame>First visit after APAP run-in at 6-8 weeks</time_frame>
    <description>The aim of this study is to establish APAP as an effective treatment modality for OSAS in the pediatric population. We hypothesize that APAP can effectively approximate the pressure determined by PSG CPAP titration as measured by the average 90th pressure percentile and average CPAP pressure delivered to the patient. The in-lab CPAP titration PSG following initial diagnosis of OSA is the current standard of therapy. APAP would potentially bridge the gap between the time of diagnosis and the follow up PSG for CPAP titration, allowing for more prompt intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence Comparison of APAP vs.CPAP (% Days Device Used and % Days Device Used &gt;4 Hours)</measure>
    <time_frame>end of study visit at 12-16 weeks</time_frame>
    <description>Randomized crossover period comparison of adherence between APAP and CPAP calculated from therapy usage hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Michigan Pediatric Sleep Questionnaire</measure>
    <time_frame>12-16 weeks</time_frame>
    <description>Comparison of Michigan pediatric sleep questionnaire score between baseline (at time of enrollment in the study) and each group (APAP, CPAP) after randomization period for the 10 subjects who completed the study. The scale range is from 0 to 1, Normal &lt;0.33, at risk is 0.33-0.55 and &gt;0.55 abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale Questionnaire</measure>
    <time_frame>12-16 weeks</time_frame>
    <description>Comparison of Epworth Sleepiness scale questionnaire score between baseline (at time of enrollment in the study) and each group (APAP, CPAP) after randomization period for the 10 subjects who completed the study. The scale range is from 0 to 24, with a value of 10 or greater suggesting significance for sleep disordered breathing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Pediatric Quality of Life Inventory Questionnaire Score Between Baseline and Each Randomization Period</measure>
    <time_frame>12-16 weeks</time_frame>
    <description>Comparison of Pediatric Quality of Life Inventory questionnaire score between baseline (at time of enrollment in the study) and each group (APAP, CPAP) after randomization period for the 10 subjects who completed the study. The scale scores range between 0-100. Higher scores indicate better health related quality of life. Healthy: 81.34-100, at risk: 81.33-65.4, unhealthy &lt;65.4</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Group 1 crossover treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks APAP settings then 4 weeks CPAP settings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 crossover treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks CPAP settings then 4 weeks APAP settings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APAP pressurized comparison</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomization periods for 6-8 weeks. An in-hospital APAP titration study will average 90th pressure percentile and average CPAP pressure derived from the device will be compared to the CPAP pressure determined by CPAP titration PSG. Subjects will then be randomized to Group 1 first, or Group 2 first, then crossover to the other group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>crossover treatment (REMstar Auto A-Flex)</intervention_name>
    <description>All subjects will use same device with 4 week crossover of settings of APAP and CPAP</description>
    <arm_group_label>APAP pressurized comparison</arm_group_label>
    <arm_group_label>Group 1 crossover treatment</arm_group_label>
    <arm_group_label>Group 2 crossover treatment</arm_group_label>
    <other_name>REMstar Auto A-Flex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  5 to 20 years of age&#xD;
&#xD;
          -  apnea hypopnea index (AHI) of â‰¥5 or obstructive hypoventilation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  significant cranio-facial abnormalities&#xD;
&#xD;
          -  chromosomal abnormalities that would affect compliance&#xD;
&#xD;
          -  cerebral palsy&#xD;
&#xD;
          -  significant neurological disease or neuromuscular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Narong Simakajornboon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neepa Gurbani, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2013</study_first_posted>
  <results_first_submitted>September 2, 2020</results_first_submitted>
  <results_first_submitted_qc>March 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2021</results_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obstructive Sleep Apnea</keyword>
  <keyword>Pediatric Obstructive Sleep Apnea</keyword>
  <keyword>Auto PAP</keyword>
  <keyword>Auto-adjustable Positive Airway Pressure</keyword>
  <keyword>APAP</keyword>
  <keyword>CPAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data at this time.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 13, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT01846988/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>15 subjects started study procedures. 5 subjects withdrew after completing the APAP pressurized comparison phase and only 10 subjects were randomized to crossover treatment. All randomized subjects completed the study. Data analysis includes the 5 withdrawals completing APAP pressurized comparison plus the 10 subjects completing study procedures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>APAP Pressurized Comparison</title>
          <description>An in-hospital titration study will average 90th pressure percentile and average CPAP pressure derived from the device will be compared to the CPAP pressure determined by CPAP titration PSG. Subjects will then be randomized to Group 1 first, or Group 2 first, then crossover to the other group.</description>
        </group>
        <group group_id="P2">
          <title>Group 1</title>
          <description>Randomized to APAP for 4 weeks followed by crossover to CPAP for 4 weeks after APAP settings for 4-8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Group 2</title>
          <description>Randomized to CPAP for 4 weeks followed by crossover to APAP for 4 weeks after APAP settings for 4-8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>APAP Pressurize Comparison (4-8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention #1 - 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5">Only 10 of 15 participants completing Comparison period started periods 1 &amp; 2</participants>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention #2 - 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data for all 15 subjects at baseline was analyzed.</population>
      <group_list>
        <group group_id="B1">
          <title>APAP Pressurized Comparison</title>
          <description>Comparison usage to determine APAP average 90% pressure (APAP P90) for initial treatment period and to assess adherence for randomization periods for 6-8 weeks or 4-6 weeks.&#xD;
Subjects will then be randomized to Group 1 first, or Group 2 first, then crossover to the other group.</description>
        </group>
        <group group_id="B2">
          <title>Group 1 Crossover Treatment</title>
          <description>Randomized to APAP for 4 weeks followed by crossover to CPAP for 4 weeks after APAP settings for 4-8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Group 2 Crossover Treatment</title>
          <description>Randomized to CPAP for 4 weeks followed by crossover to APAP for 4 weeks after APAP settings for 4-8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.3" spread="3.1"/>
                    <measurement group_id="B4" value="14.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference Between Optimal Pressure (cm H2O) Derived From APAP run-in Period Versus Result of CPAP Titration Study</title>
        <description>The aim of this study is to establish APAP as an effective treatment modality for OSAS in the pediatric population. We hypothesize that APAP can effectively approximate the pressure determined by PSG CPAP titration as measured by the average 90th pressure percentile and average CPAP pressure delivered to the patient. The in-lab CPAP titration PSG following initial diagnosis of OSA is the current standard of therapy. APAP would potentially bridge the gap between the time of diagnosis and the follow up PSG for CPAP titration, allowing for more prompt intervention.</description>
        <time_frame>First visit after APAP run-in at 6-8 weeks</time_frame>
        <population>The APAP pressure comparison group included 15 participants. After this initial period, 5 participants withdrew from the study. The remaining 10 participants were randomized to Group 1 or 2.</population>
        <group_list>
          <group group_id="O1">
            <title>APAP Pressure Comparison</title>
            <description>APAP pressure comparison period was 6-8 weeks. APAP average 90th pressure percentile derived from machine download was compared to CPAP pressure determined by CPAP titration PSG. Subjects will then be randomized to Group 1 first, or Group 2 first, then crossover to the other group.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between Optimal Pressure (cm H2O) Derived From APAP run-in Period Versus Result of CPAP Titration Study</title>
          <description>The aim of this study is to establish APAP as an effective treatment modality for OSAS in the pediatric population. We hypothesize that APAP can effectively approximate the pressure determined by PSG CPAP titration as measured by the average 90th pressure percentile and average CPAP pressure delivered to the patient. The in-lab CPAP titration PSG following initial diagnosis of OSA is the current standard of therapy. APAP would potentially bridge the gap between the time of diagnosis and the follow up PSG for CPAP titration, allowing for more prompt intervention.</description>
          <population>The APAP pressure comparison group included 15 participants. After this initial period, 5 participants withdrew from the study. The remaining 10 participants were randomized to Group 1 or 2.</population>
          <units>cmH2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>APAP 90 percent pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPAP titration PSG pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adherence Comparison of APAP vs.CPAP (% Days Device Used and % Days Device Used &gt;4 Hours)</title>
        <description>Randomized crossover period comparison of adherence between APAP and CPAP calculated from therapy usage hours.</description>
        <time_frame>end of study visit at 12-16 weeks</time_frame>
        <population>For data analysis we combined APAP data together and CPAP data together regardless of the order of randomization, yielding 10 subjects for APAP adherence and 10 subjects for CPAP adherence. In the data analysis below the column labeled Group 1 contains all APAP data and Group 2 contains all CPAP data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Combined APAP data regardless of the order of randomization</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Combined CPAP data regardless of order of randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence Comparison of APAP vs.CPAP (% Days Device Used and % Days Device Used &gt;4 Hours)</title>
          <description>Randomized crossover period comparison of adherence between APAP and CPAP calculated from therapy usage hours.</description>
          <population>For data analysis we combined APAP data together and CPAP data together regardless of the order of randomization, yielding 10 subjects for APAP adherence and 10 subjects for CPAP adherence. In the data analysis below the column labeled Group 1 contains all APAP data and Group 2 contains all CPAP data.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% days device used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="27.2"/>
                    <measurement group_id="O2" value="61.4" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% days device used &gt;4h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="29.0"/>
                    <measurement group_id="O2" value="44.3" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Michigan Pediatric Sleep Questionnaire</title>
        <description>Comparison of Michigan pediatric sleep questionnaire score between baseline (at time of enrollment in the study) and each group (APAP, CPAP) after randomization period for the 10 subjects who completed the study. The scale range is from 0 to 1, Normal &lt;0.33, at risk is 0.33-0.55 and &gt;0.55 abnormal.</description>
        <time_frame>12-16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Michigan pediatric questionnaire score obtained at baseline at the time of enrollment into the study for subjects who were then randomized to APAP and CPAP.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Michigan pediatric sleep questionnaire score administered after APAP randomization period regardless of the order of randomization.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Michigan pediatric sleep questionnaire score administered after CPAP randomization period regardless of the order of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Michigan Pediatric Sleep Questionnaire</title>
          <description>Comparison of Michigan pediatric sleep questionnaire score between baseline (at time of enrollment in the study) and each group (APAP, CPAP) after randomization period for the 10 subjects who completed the study. The scale range is from 0 to 1, Normal &lt;0.33, at risk is 0.33-0.55 and &gt;0.55 abnormal.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.2"/>
                    <measurement group_id="O2" value="0.44" spread="0.2"/>
                    <measurement group_id="O3" value="0.39" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epworth Sleepiness Scale Questionnaire</title>
        <description>Comparison of Epworth Sleepiness scale questionnaire score between baseline (at time of enrollment in the study) and each group (APAP, CPAP) after randomization period for the 10 subjects who completed the study. The scale range is from 0 to 24, with a value of 10 or greater suggesting significance for sleep disordered breathing.</description>
        <time_frame>12-16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Epworth sleepiness scale questionnaire data obtained at baseline at the time of enrollment into the study for subjects who were then randomized to APAP and CPAP.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Epworth sleepiness scale questionnaire data administered after APAP randomization period regardless of the order of randomization.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Epworth sleepiness scale questionnaire data administered after CPAP randomization period regardless of the order of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Epworth Sleepiness Scale Questionnaire</title>
          <description>Comparison of Epworth Sleepiness scale questionnaire score between baseline (at time of enrollment in the study) and each group (APAP, CPAP) after randomization period for the 10 subjects who completed the study. The scale range is from 0 to 24, with a value of 10 or greater suggesting significance for sleep disordered breathing.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="6.2"/>
                    <measurement group_id="O2" value="7.6" spread="5.0"/>
                    <measurement group_id="O3" value="7.2" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Pediatric Quality of Life Inventory Questionnaire Score Between Baseline and Each Randomization Period</title>
        <description>Comparison of Pediatric Quality of Life Inventory questionnaire score between baseline (at time of enrollment in the study) and each group (APAP, CPAP) after randomization period for the 10 subjects who completed the study. The scale scores range between 0-100. Higher scores indicate better health related quality of life. Healthy: 81.34-100, at risk: 81.33-65.4, unhealthy &lt;65.4</description>
        <time_frame>12-16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Pediatric Quality of Life Inventory questionnaire data obtained at baseline at the time of enrollment into the study for subjects who were then randomized to APAP and CPAP.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Pediatric Quality of Life Inventory questionnaire data administered after APAP randomization period regardless of the order of randomization.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Pediatric Quality of Life Inventory questionnaire data administered after CPAP randomization period regardless of the order of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pediatric Quality of Life Inventory Questionnaire Score Between Baseline and Each Randomization Period</title>
          <description>Comparison of Pediatric Quality of Life Inventory questionnaire score between baseline (at time of enrollment in the study) and each group (APAP, CPAP) after randomization period for the 10 subjects who completed the study. The scale scores range between 0-100. Higher scores indicate better health related quality of life. Healthy: 81.34-100, at risk: 81.33-65.4, unhealthy &lt;65.4</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="17.9"/>
                    <measurement group_id="O2" value="65.9" spread="20.2"/>
                    <measurement group_id="O3" value="68.5" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment start until study completion, an average of 16 weeks</time_frame>
      <desc>The arms/groups are combined to maintain the format used for reporting outcomes. There were no adverse events to report in the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>APAP Pressurized Comparison</title>
          <description>randomization periods for 6-8 weeks.&#xD;
An in-hospital APAP titration study will average 90th pressure percentile and average CPAP pressure derived from the device will be compared to the CPAP pressure determined by CPAP titration PSG. Subjects will then be randomized to Group 1 first, or Group 2 first, then crossover to the other group.</description>
        </group>
        <group group_id="E2">
          <title>Group 1 Crossover Treatment</title>
          <description>crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks APAP settings then 4 weeks CPAP settings.&#xD;
crossover treatment (REMstar Auto A-Flex): All subjects will use same device with 4 week crossover of settings of APAP and CPAP</description>
        </group>
        <group group_id="E3">
          <title>Group 2 Crossover Treatment</title>
          <description>crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks CPAP settings then 4 weeks APAP settings.&#xD;
crossover treatment (REMstar Auto A-Flex): All subjects will use same device with 4 week crossover of settings of APAP and CPAP</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size, small number of pre-adolescent subjects, and short term study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Neepa Gurbani, Assistant Professor</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>(513) 736-1814</phone>
      <email>Neepa.Gurbani@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

